Quantcast

Latest Ardelyx Inc. Stories

2014-10-01 08:30:24

-- Primary endpoint was met for 50 mg twice daily dosing -- FREMONT, Calif., Oct. 1, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced positive results from its 371 patient Phase 2b clinical trial evaluating tenapanor in patients with constipation-predominant irritable bowel syndrome (IBS-C). Results from this study demonstrated statistically significant and...

2014-09-05 08:24:15

FREMONT, Calif., Sept. 5, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Dominique Charmot, Ph.D., the Company's Chief Scientific Officer, has announced his retirement from Ardelyx, effective December 23, 2014. Dr. Charmot cited personal reasons for his departure, including his desire to spend more time with his family. "Dominique has been a vital...

2014-08-05 08:35:41

FREMONT, Calif., Aug. 5, 2014 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that Mike Raab, Ardelyx's President and Chief Executive Officer, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 2:30pm Eastern Time at the Le Parker Meridien Hotel in New York City. Individuals who are interested in listening...

2014-06-24 16:24:52

FREMONT, Calif., June 24, 2014 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the closing of its initial public offering of 4,928,900 shares of common stock at an initial public offering price of $14.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 642,900 additional shares of common stock. All of the shares of common...

2014-06-19 00:21:17

FREMONT, Calif., June 18, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced the pricing of its initial public offering of 4,286,000 shares of common stock at a public offering price of $14.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "ARDX" on June 19, 2014. In addition, Ardelyx has granted the underwriters a 30-day option to...

2014-05-15 08:32:20

Study will evaluate tenapanor for the treatment of hyperphosphatemia in ESRD patients on hemodialysis FREMONT, Calif., May 15, 2014 /PRNewswire/ -- Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on cardio-renal, GI and metabolic diseases, today announced that it has received a $25 million milestone payment from AstraZeneca (NYSE:AZN, LON:AZN) for the initiation of a Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, or elevated...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related